
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Updates on the Diabetes drug market.
over 16 years ago
Applied Clinical Trials Digital Edition - August 2010, Supplementover 16 years ago
Applied Clinical Trials Digital Edition - August 2010over 16 years ago
Business and News Update August 2010over 16 years ago
Automating Phase I Trialsover 16 years ago
Key Updates to the 1572over 16 years ago
Considerations for Medical Device Trialsover 16 years ago
Triggered Monitoringover 16 years ago
Foreign Clinical Trials Under Scrutinyover 16 years ago
Deconstructing Relative Effectiveness Effortsover 16 years ago
Effective Comparisons: Baseball and CER





